Features of MCTD associated transverse myelopathy
|
Report 1st author | Duration of MCTD (y) | Age | Sex | Onset | Site | Treatment | Neurological outcome | Imaging | ||||||||
| Current | 2 | 46 | M | Progressive over 3 months | Thoracic | Pred/Aza | No change | Spinal MRI cord atrophy | ||||||||
| Mok1 | 2 | 46 | F | Progressive | Thoracic | Pred/Aza/Anticoagulation | Improved. Power increased from 3–4 over 4 months | Spinal MRI normal | ||||||||
| Flechtner2 | 5 | 19 | F | Progressive with a subsequent relapsing course | Thoracic and Cervical | Pred/Aza/Plasmapheresis | Each “relapse” resolved. | Spinal MRI high signal intramedullary lesion | ||||||||
| Sequlae: mild sensory disturbances | ||||||||||||||||
| 1-150Obara3 | n/k | 42 | F | Progressive | Thoracic | Pred/Aza | Resolved. Sequelae: painful tonic spasm | Spinal MRI abnormal | ||||||||
| 1-150Yamaguchi4 | n/k | 53 | F | Progressive | Thoracic | Pred | Improved | n/k | ||||||||
| Pedersen5 | 2 | 16 | F | Progressive over less than 1 week | Thoracic | Pred/Aza | Resolved. Sequelae: urge incontinence | CT brain normal. | ||||||||
| No spinal CT | ||||||||||||||||
| Weiss6 | 1 | 24 | F | Progressive over 4 weeks | Thoracic | Pred/Aza | No change | n/k | ||||||||
(Pred=Prednisolone; Aza=azathioprine; n/k=not known);
↵1-150 Japanese journal, English abstract only.